Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
FOLD's Cash to Debt is ranked higher than
87% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. FOLD: No Debt )
Ranked among companies with meaningful Cash to Debt only.
FOLD' s 10-Year Cash to Debt Range
Min: 4.97  Med: 52.30 Max: No Debt
Current: No Debt
F-Score: 3
Z-Score: 12.68
M-Score: -5.14
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -11694.66
FOLD's Operating margin (%) is ranked lower than
94% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -71.14 vs. FOLD: -11694.66 )
Ranked among companies with meaningful Operating margin (%) only.
FOLD' s 10-Year Operating margin (%) Range
Min: -17680.72  Med: -1430.62 Max: -11.42
Current: -11694.66
-17680.72
-11.42
Net-margin (%) -11691.41
FOLD's Net-margin (%) is ranked lower than
94% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -67.10 vs. FOLD: -11691.41 )
Ranked among companies with meaningful Net-margin (%) only.
FOLD' s 10-Year Net-margin (%) Range
Min: -16427.82  Med: -1286.28 Max: -10.2
Current: -11691.41
-16427.82
-10.2
ROE (%) -70.74
FOLD's ROE (%) is ranked lower than
71% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. FOLD: -70.74 )
Ranked among companies with meaningful ROE (%) only.
FOLD' s 10-Year ROE (%) Range
Min: -322.07  Med: -88.03 Max: -9.19
Current: -70.74
-322.07
-9.19
ROA (%) -42.76
FOLD's ROA (%) is ranked lower than
64% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. FOLD: -42.76 )
Ranked among companies with meaningful ROA (%) only.
FOLD' s 10-Year ROA (%) Range
Min: -3515.77  Med: -50.19 Max: -6.13
Current: -42.76
-3515.77
-6.13
ROC (Joel Greenblatt) (%) -2826.92
FOLD's ROC (Joel Greenblatt) (%) is ranked lower than
73% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. FOLD: -2826.92 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
FOLD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1978.21  Med: -1314.93 Max: -134.99
Current: -2826.92
-1978.21
-134.99
Revenue Growth (3Y)(%) -68.20
FOLD's Revenue Growth (3Y)(%) is ranked lower than
88% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. FOLD: -68.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
FOLD' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -68.20 Max: -2.6
Current: -68.2
EBITDA Growth (3Y)(%) -12.40
FOLD's EBITDA Growth (3Y)(%) is ranked lower than
62% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. FOLD: -12.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
FOLD' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -13.40 Max: 82.8
Current: -12.4
0
82.8
EPS Growth (3Y)(%) -10.10
FOLD's EPS Growth (3Y)(%) is ranked lower than
53% of the 418 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. FOLD: -10.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
FOLD' s 10-Year EPS Growth (3Y)(%) Range
Min: -85.2  Med: -14.20 Max: 59.5
Current: -10.1
-85.2
59.5
» FOLD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

FOLD Guru Trades in Q3 2014

RS Investment Management 1,248,215 sh (New)
Charles Brandes 36,700 sh (New)
Paul Tudor Jones 78,079 sh (New)
Jim Simons 130,400 sh (New)
Steven Cohen 195,900 sh (New)
Chuck Royce Sold Out
George Soros Sold Out
» More
Q4 2014

FOLD Guru Trades in Q4 2014

Louis Moore Bacon 225,000 sh (New)
Jim Simons 508,700 sh (+290.11%)
RS Investment Management 2,850,955 sh (+128.40%)
Paul Tudor Jones 98,522 sh (+26.18%)
Steven Cohen Sold Out
Charles Brandes Sold Out
» More
Q1 2015

FOLD Guru Trades in Q1 2015

Steven Cohen 173,900 sh (New)
Jim Simons Sold Out
RS Investment Management 2,564,545 sh (-10.05%)
Louis Moore Bacon 140,641 sh (-37.49%)
Paul Tudor Jones 11,620 sh (-88.21%)
» More
Q2 2015

FOLD Guru Trades in Q2 2015

Chuck Royce 380,000 sh (New)
Paul Tudor Jones 106,356 sh (+815.28%)
Steven Cohen 916,700 sh (+427.14%)
Louis Moore Bacon 275,000 sh (+95.53%)
RS Investment Management 2,687,065 sh (+4.78%)
RS Investment Management 2,687,065 sh (+4.78%)
» More
» Details

Insider Trades

Latest Guru Trades with FOLD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.38
FOLD's P/B is ranked lower than
59% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. FOLD: 5.38 )
Ranked among companies with meaningful P/B only.
FOLD' s 10-Year P/B Range
Min: 0.87  Med: 3.27 Max: 15.92
Current: 5.38
0.87
15.92
P/S 4604.75
FOLD's P/S is ranked lower than
179% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.47 vs. FOLD: 4604.75 )
Ranked among companies with meaningful P/S only.
FOLD' s 10-Year P/S Range
Min: 0  Med: 12.78 Max: 4604.75
Current: 4604.75
0
4604.75
Current Ratio 21.60
FOLD's Current Ratio is ranked higher than
92% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. FOLD: 21.60 )
Ranked among companies with meaningful Current Ratio only.
FOLD' s 10-Year Current Ratio Range
Min: 3.46  Med: 7.79 Max: 21.6
Current: 21.6
3.46
21.6
Quick Ratio 21.60
FOLD's Quick Ratio is ranked higher than
92% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. FOLD: 21.60 )
Ranked among companies with meaningful Quick Ratio only.
FOLD' s 10-Year Quick Ratio Range
Min: 3.46  Med: 7.79 Max: 21.6
Current: 21.6
3.46
21.6

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.16
FOLD's Price/Net Cash is ranked higher than
57% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. FOLD: 6.16 )
Ranked among companies with meaningful Price/Net Cash only.
FOLD' s 10-Year Price/Net Cash Range
Min: 1.06  Med: 3.80 Max: 148.75
Current: 6.16
1.06
148.75
Price/Net Current Asset Value 6.09
FOLD's Price/Net Current Asset Value is ranked higher than
54% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 6.84 vs. FOLD: 6.09 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
FOLD' s 10-Year Price/Net Current Asset Value Range
Min: 1.02  Med: 3.61 Max: 99.17
Current: 6.09
1.02
99.17
Price/Tangible Book 5.99
FOLD's Price/Tangible Book is ranked lower than
54% of the 690 Companies
in the Global Biotechnology industry.

( Industry Median: 5.33 vs. FOLD: 5.99 )
Ranked among companies with meaningful Price/Tangible Book only.
FOLD' s 10-Year Price/Tangible Book Range
Min: 0.96  Med: 3.43 Max: 54.09
Current: 5.99
0.96
54.09
Earnings Yield (Greenblatt) (%) -6.36
FOLD's Earnings Yield (Greenblatt) (%) is ranked lower than
51% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. FOLD: -6.36 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
FOLD' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -6.74  Med: 139.40 Max: 3784.9
Current: -6.36
-6.74
3784.9

Analyst Estimate

Dec15 Dec16
Revenue(Mil) 31
EPS($) -1.36 -1.35
EPS without NRI($) -1.36 -1.35

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AM6.Germany,
Amicus Therapeutics Inc incorporated under the laws of the State of Delaware on February 4, 2002. The Company is a Biopharmaceutical Company focused on the discovery, development and commercialization of next-generation medicines for a range of rare and orphan diseases, with a focus on improved therapies for lysosomal storage disorders (LSDs). IT is focused on developing pharmacological chaperones as monotherapy agents (to be used without ERT) and its Chaperone-Advanced Replacement Therapy, or CHART platform of pharmacological chaperones in combination with ERT. Chaperone-Advanced Replacement Therapy, or CHART, platform has been used to develop our next-generation ERTs by co-formulating therapeutic enzymes with our proprietary pharmacological chaperones. It is also developing migalastat HCl as a monotherapy in two Phase 3 global registration studies ("Study 011" and "Study 012") for Fabry patients with genetic mutations that were amenable to this pharmacological chaperone in a cell-based assay. Study 011 is a 24-month study consisting of a 6-month double-blind, placebo-controlled treatment period (Stage 1); a 6-month open-label follow-up period (Stage 2); and a 12-month open-label extension phase. The Company currently operates in one business segment focusing on the development and commercialization of small molecule, orally administered therapies to treat a range of human genetic diseases. Its major competitors include pharmaceutical and biotechnology companies in the U.S. and abroad that have approved therapies or therapies in development for lysosomal storage disorders within our core programs. The Company owns certain trademarks in the U.S. and/or abroad, including A AMICUS THERAPEUTICS & design, AMICUS THERAPEUTICS and CHART.
» More Articles for FOLD

Headlines

Articles On GuruFocus.com
yl Jul 21 2015 
Weekly CEO Sells Highlight: Globus Medical Inc, Diplomat Pharmacy Inc, Zendesk Inc, and Amicus Thera Mar 28 2015 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Nov 09 2010 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Aug 06 2010 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) May 07 2010 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Nov 04 2009 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Aug 06 2009 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) May 08 2009 
iwillbeback note on FOLD Sep 03 2008 

More From Other Websites
Can Durham's Scioderm reach the $1 billion carrot? Sep 02 2015
Biotech Stock Roundup: Amgen in the News, ARIAD a Takeover Target? Sep 02 2015
Amicus (FOLD) Signs Agreement to Acquire Scioderm Sep 01 2015
Durham drug developer sold to Amicus Therapeutics in deal worth up to $947M Aug 31 2015
AMICUS THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 31 2015
Early movers: BAC, JCP, TWTR, UTX, GS, PSX & more Aug 31 2015
Amicus Therapeutics to Acquire Rare Disease Company Scioderm, Inc. Aug 31 2015
Amicus Acquires Scioderm, Adds Drug for Rare Skin Disorder to Pipeline Aug 31 2015
Amicus Therapeutics to Acquire Rare Disease Company Scioderm, Inc. Aug 31 2015
AMICUS THERAPEUTICS INC Financials Aug 14 2015
10-Q for Amicus Therapeutics, Inc. Aug 07 2015
Amicus Therapeutics reports 2Q loss Aug 05 2015
Amicus Therapeutics reports 2Q loss Aug 05 2015
AMICUS THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 05 2015
Amicus Therapeutics Announces Second Quarter 2015 Financial Results and Corporate Updates Aug 05 2015
Amicus Therapeutics Announces Second Quarter 2015 Financial Results and Corporate Updates Aug 05 2015
Q2 2015 Amicus Therapeutics Inc Earnings Release - After Market Close Aug 05 2015
5 stocks to watch Jul 29 2015
Huge Buying For 5 Stocks On Russell Index Month End Changes Jul 29 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK